leadf
logo-loader
viewInvitrocue Ltd

Invitrocue signs agreement to develop new breast cancer models for its Onco-PDO test

The collaboration agreement is an important advancement for Invitrocue to expand into multiple subtypes of the world’s leading cancer for women.

a woman holding a ribbon
Evidence-based approach to inform treatment pathways

Invitrocue Ltd (ASX:IVQ) has signed a new technology development agreement with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB) for the development of new breast cancer models for its proprietary Onco-PDO test.

The Onco-PDO technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients.

 

 

Under the agreement, professor Arial Zeng, an expert in stem cells during mammary development and breast cancer, will help Invitrocue to develop and optimise the protocols for the in vitro culture, propagation and expansion of patient-derived organoids (PDOs) from breast cancer patients with multiple breast cancer subtypes, including ER+, PR+, HER2+ and TNBC.

The intellectual property (IP) will be jointly owned by both parties and Invitrocue will be granted global commercialisation rights to any IP developed under the agreement.

Invitrocue executive chairman Dr. Steven Fang said: “Whilst we already offer breast cancer testing with Onco-PDOTM, this collaboration agreement is an important advancement of our technology to expand into multiple subtypes of the world’s leading cancer for women.

“Professor Arial Zeng is a world-renowned scientist in breast cancer organoid biology, and we look forward to working closely with her.

“This collaboration will enable us to provide even more precise and personalised data for breast cancer patients, leveraging our evidence-based approach to inform treatment pathways and improve patient outcomes.”

Quick facts: Invitrocue Ltd

Price: - AUD

ASX:IVQ
Market: ASX
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Invitrocue Ltd named herein, including the promotion by the Company of Invitrocue Ltd in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read